- Home
- DCH vs NNNN Comparison
DCH vs NNNN Comparison
Compare DCH & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCH | NNNN |
|---|---|---|
| Founded | 1994 | 2021 |
| Country | United States | Germany |
| Employees | 18000 | 27 |
| Industry | Auto Parts:O.E.M. | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DCH | NNNN |
|---|---|---|
| Price | $5.34 | $9.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 45.3K |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $82.65 | N/A |
| Revenue Next Year | $4.20 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.92 | $8.30 |
| 52 Week High | $8.75 | $54.90 |
Technical Indicators
Market Signals| Indicator | DCH | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 26.01 |
| Support Level | $4.97 | $8.30 |
| Resistance Level | $6.30 | $30.21 |
| Average True Range (ATR) | 0.24 | 1.63 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 57.86 | 11.27 |
Price Performance
Historical ComparisonAbout DCH Dauch Corporation Common Stock
Dauch Corp is a world-wide Tier 1 Automotive Supplier, Dauch designs, engineers and manufactures Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).